The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

For decades, scientists have explored the potential of bacteria in fighting cancer, but safety and efficacy barriers have ...

Our DNA is constantly under threat — from cell division errors to external factors like sunlight and smoking. Fortunately, ...

Neuroblastoma is a solid tumor that occurs in children. When high-risk, the disease has a poor prognosis. Decades ago, adding ...

Why retinoic acid is effective in this setting but not against primary tumors, has been speculated about for nearly 50 years. Scientists resolved the mystery, showing the drug 'hijacks' a normal ...